Literature DB >> 22130456

The saxon bisphosphonate register - therapy and prevention of bisphosphonate-related osteonecrosis of the jaws.

Marika Schubert1, Ingolf Klatte, Wigbert Linek, Bianca Müller, Karli Döring, Uwe Eckelt, Alexander Hemprich, Uwe Berger, Jörg Hendricks.   

Abstract

In 2009, a study group of three Saxon hospitals set up a Saxon register with the aim of including all patients with bisphosphonate (BP) medication. In addition, specific concepts for surgical approach were developed. The target is to define relevant treatment and prevention strategies of bisphosphonate-related osteonecrosis of the jaws (BRONJ) based on high patient population statistics. Since July 2009, all patients with oral or intravenous BP medication have been registered in the 3 Saxon hospitals. Data was systematically acquired in detailed forms. Totally, 258 patients (♂: 83, ♀: 175) were registered by October 2010. 100 patients out of this already had BRONJ which preferably affected the mandible (70%) and was mostly associated with intravenous medication. In 54 cases, treatment was carried out by surgery according to the strategy developed. The criterion for success was absence of symptoms at least for 3 months after surgery. The following stage-dependent success rates were obtained: stage I (13 patients) - 84.6%, stage II (22 patients) - 95.5%, stage III (14 patients) - 85.7%, stage IV (5 patients) - 80%. Under preventive aspects, teeth were extracted after a predefined scheme in 68 of all patients registered as being asymptomatic. No BRONJ was observed in 98.5%; the criterion also being absence of symptoms for a minimum period of 3 months after surgery. Surgical treatment is the treatment of choice in cases of BRONJ. Tooth extractions are rather unproblematic in asymptomatic patients if the predefined scheme is followed.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22130456     DOI: 10.1016/j.oraloncology.2011.11.004

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  21 in total

1.  Teriparatide's role in the management of bisphosphonate-associated osteonecrosis of the jaw.

Authors:  G Subramanian; S Y P Quek
Journal:  Osteoporos Int       Date:  2012-03-10       Impact factor: 4.507

2.  The outcome after surgical therapy of bisphosphonate-associated osteonecrosis of the jaw--results of a clinical case series with an average follow-up of 20 months.

Authors:  Philipp Stockmann; Moritz Burger; Cornelius von Wilmowsky; Tobias Ebker; Rainer Lutz; Anne Bauersachs; Emeka Nkenke; Friedrich Wilhelm Neukam; Falk Wehrhan
Journal:  Clin Oral Investig       Date:  2013-08-29       Impact factor: 3.573

Review 3.  A literature review of perioperative antibiotic administration in surgery for medication-related osteonecrosis of the jaw.

Authors:  Masaya Akashi; Junya Kusumoto; Daisuke Takeda; Takashi Shigeta; Takumi Hasegawa; Takahide Komori
Journal:  Oral Maxillofac Surg       Date:  2018-10-16

Review 4.  [Bisphosphonate-associated osteonecrosis of the jaw].

Authors:  S Koy; M Schubert; J Koy; M Ney; G Lauer; R Sabatowski
Journal:  Schmerz       Date:  2015-04       Impact factor: 1.107

5.  Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.

Authors:  Petra Rugani; Gero Luschin; Norbert Jakse; Barbara Kirnbauer; Uwe Lang; Stephan Acham
Journal:  Clin Oral Investig       Date:  2013-06-10       Impact factor: 3.573

6.  Periosteal reaction of medication-related osteonecrosis of the jaw (MRONJ): clinical significance and changes during conservative therapy.

Authors:  Sakiko Soutome; Mitsunobu Otsuru; Saki Hayashida; Souichi Yanamoto; Miho Sasaki; Yukinori Takagi; Misa Sumi; Yuka Kojima; Shunsuke Sawada; Hiroshi Iwai; Masahiro Umeda; Toshiyuki Saito
Journal:  Support Care Cancer       Date:  2021-04-21       Impact factor: 3.603

7.  Retrospective Analysis of Treatment Outcomes of Maxillary Sinusitis Associated with Medication-Related Osteonecrosis of the Jaw.

Authors:  Mitsunobu Otsuru; Saki Hayashida; Kota Morishita; Maho Murata; Sakiko Soutome; Miho Sasaki; Yukinori Takagi; Misa Sumi; Masahiro Umeda
Journal:  Int J Environ Res Public Health       Date:  2022-06-17       Impact factor: 4.614

8.  Relationship between drug holiday of the antiresorptive agents and surgical outcome of medication-related osteonecrosis of the jaw in osteoporosis patients.

Authors:  Kota Morishita; Sakiko Soutome; Mitsunobu Otsuru; Saki Hayashida; Maho Murata; Miho Sasaki; Yukinori Takagi; Misa Sumi; Masahiro Umeda
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

Review 9.  Surgical management of bisphosphonate-related osteonecrosis of the jaws: literature review.

Authors:  Larissa Fernandes Silva; Cláudia Curra; Marcelo Salles Munerato; Carlos Cesar Deantoni; Mariza Akemi Matsumoto; Camila Lopes Cardoso; Marcos Martins Curi
Journal:  Oral Maxillofac Surg       Date:  2015-12-11

Review 10.  Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Authors:  Athanasios D Anastasilakis; Jessica Pepe; Nicola Napoli; Andrea Palermo; Christos Magopoulos; Aliya A Khan; M Carola Zillikens; Jean-Jacques Body
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.